Zheng Quan Shi Bao Wang·2025-12-03 09:13Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]